Daily non-political popular news in brief.

Combination therapy stops loss of kidney function in rare genetic disease

A combination of two types of blood pressure-lowering drugs -- an angiotensin-converting enzyme inhibitor (ACEI) plus an angiotensin-receptor blocker (ARB), added to enzyme replacement therapy (ERT) with agalsidase-beta (Fabrazyme, Genzyme Corporation, Cambridge, Mass.) -- is the first treatment shown to stop progressive loss of kidney function in patients with severe kidney involvement due to the rare genetic disorder Fabry disease, reports a study in the September Journal of the American Society of Nephrology.

Read more »

Keywords: combination, therapy, stops, loss, kidney, function, rare, genetic, disease, stop

« Previous | Next »

Similar news on "Combination therapy stops loss of kidney function in rare genetic disease":

1. Origin of inherited pain disorder pinpointed
   12-06-2006 · EurekAlert!
   The genetic basis for a rare inherited disorder that causes severe burning pain with no warning has been pinpointed by researchers. They found that paroxysmal extreme pain disorder (PEPD) is caused by specific mutations in porelike sodium channels in peripheral nerve cells -- a discovery that they said emphasizes the role of such channel disorders in inflammatory pain. Such findings of abnormal function in disease also provide insights into the normal function of such channels, they said.
   Similar news · Read more »
   
2. Treatment discovered for deadly childhood disease
   12-06-2006 · EurekAlert!
   Researchers have discovered that a treatment involving enzyme replacement therapy dramatically reduces the risk of death in children with Pompe disease, a rare genetic disorder in which most children die before their first birthday. The disorder causes profound muscle weakness and heart and breathing problems and affects as many as one in 40,000 births. The study is published in the online edition of Neurology, the scientific journal of the American Academy of Neurology.
   Similar news · Read more »
   
3. Scientists find new agent to fight genetic disorders -- Zorro-Locked Nucleic Acid
   04-30-2007 · EurekAlert!
   A new agent, "Zorro-LNA," may stop some genetic disorders in their tracks. An article appearing in The FASEB Journal's June 2007 issue describes how researchers developed Zorro-LNA to bind with both strands of a gene's DNA, effectively disabling it. This has clinical implications for virtually every condition caused or worsened by dominant defective genes, such as: Huntington's disease, familial high cholesterol, polycystic kidney disease, some instances of glaucoma and colorectal cancer, and neurofibromatosis, among others.
   Similar news · Read more »
   
4. Advance in understanding of blood pressure gene could lead to new treatments
   02-04-2007 · EurekAlert!
   Research by scientists at UCL (University College London) has clearly demonstrated for the first time the structure and function of a gene crucial to the regulation of blood pressure. The discovery could be important in the search for new treatments for illnesses such as heart disease, the UK's biggest killer. In a paper published online today in Nature Medicine, the team, led by Professor Patrick Vallance and Dr James Leiper, UCL Department of Medicine, reveal the role of the human gene dimethylarginine dimethylaminohydrolase (DDAH), showing that loss of DDAH activity disrupts nitric oxide (NO) production. NO is critical in the regulation of blood pressure, nervous system functions and the immune system. The role of DDAH is to break down modified amino acids (Asymmetric dimethylarginine (ADMA) and monomethyl arginine (L-NMMA)) that are produced by the body and have been shown to inhibit NO synthase. These molecules accumulate in various disease states including diabetes, renal failure and pulmonary and systemic hypertension, and their concentration in plasma (the fluid component of blood) is strongly predicative of cardiovascular disease and death. In a healthy human body, the majority of ADMA is eliminated through active metabolism by DDAH. Scientists have hypothesised that if DDAH function is impaired, NO production is reduced, and that this could be an important feature of increased cardiovascular risk. To examine this pathway in more detail, the researchers deleted the DDAH gene in mice. These mice went on to develop hypertension, or high blood pressure. They also designed specific inhibitors (small molecules) which bind to the active site of human DDAH. These small molecule inhibitors also induced hypertension in mice, confirming the importance of DDAH in the regulation of blood pressure. Dr Leiper, UCL Medicine, said: “These genetic and chemical approaches to disrupt DDAH showed remarkably consistent results, and provide compelling evidence that loss of DDAH function increases the concentration of ADMA and thereby disrupts vascular NO signalling. “There has been considerable scientific interest in this pathway and the role of ADMA as a novel risk factor, but so far there's been little evidence to support the idea that it's a cause of disease, rather than just a marker. Genes and their pathways are crucial to our understanding of cardiovascular disease and a better understanding of DDAH-1 could lead to important new treatments. “It could help us to establish if genetic variation predisposes certain people to these diseases, or whether environmental factors exert some of their effects through modulation of DDAH activity. “Our research also shows that this pathway could be harnessed therapeutically to limit production of NO in certain situations where too much nitric oxide is a bad thing; for example, hypotension and septic shock. These are some of the biggest problems in intensive care medicine and there is a huge unmet need for drug treatments.” The study, which was carried out at UCL's Rayne Institute, was funded by grants from the British Heart Foundation, the Wellcome Trust and the Medical Research Council. Professor Jeremy Pearson, Associate Medical Director of the British Heart Foundation, said: "The unexpected finding in the 1980s that a simple gas, nitric oxide (NO), is made by cells in the blood vessel wall and is a powerful control of blood vessel relaxation led to the award of the Nobel Prize in 1998 to its discoverers. "More recently, there has been increasing evidence that impairment of NO production is likely to be an important factor in the development of heart and circulatory disease, but the mechanisms responsible are not fully understood. "This study suggests for the first time that the loss of the activity of the enzyme DDAH-1 leads to reduced NO production and may cause heart and circulatory disease. These findings are likely to be important in the search for new ways to optimise the health of our blood vessels." ### Notes for Editors 1. For more information, please contact Ruth Metcalfe in the UCL Media Relations Office on tel: +44 (0)20 7679 9739, mobile: +44 (0)7990 675 947, out of hours: +44 (0)7917 271 364, e-mail: r.metcalfe@ucl.ac.uk2. 'Disruption of methylarginine metabolism impairs vascular homeostasis' is published in the February issue of the journal Nature Medicine. Advance online publication is embargoed to 18.00 GMT (13.00 US Eastern) Sunday 4 February 2007. Journalists can obtain copies of the paper by contacting the UCL Media Relations Office.3. The study was funded by the British Heart Foundation, the Wellcome Trust and the Medical Research Council. About UCL Founded in 1826, UCL was the first English university established after Oxford and Cambridge, the first to admit students regardless of race, class, religion or gender, and the first to provide systematic teaching of law, architecture and medicine. In the government's most recent Research Assessment Exercise, 59 UCL departments achieved top ratings of 5* and 5, indicating research quality of international excellence. UCL is the fourth-ranked UK university in the 2006 league table of the top 500 world universities produced by the Shanghai Jiao Tong University. UCL alumni include Mahatma Gandhi (Laws 1889, Indian political and spiritual leader); Jonathan Dimbleby (Philosophy 1969, writer and television presenter); Junichiro Koizumi (Economics 1969, Prime Minister of Japan); Lord Woolf (Laws 1954, Lord Chief Justice of England & Wales); Alexander Graham Bell (Phonetics 1860s, inventor of the telephone), and members of the band Coldplay.
   Similar news · Read more »
   
5. JCI table of contents: June 7, 2007
   06-07-2007 · EurekAlert!
   This release contains summaries, links to PDFs, and contact information for the following newsworthy papers to be published online June 7, 2007, in the JCI, including: "Combination therapy reduces tumor resistance to radiation"; "Improved prediction of prostate cancer recurrence"; "Role of GM-CSF in the immune response to tumors"; "Protein C signaling impacts inflammatory bowel disease"; "Iron imbalance in anemia: Hints from HIF"; and "Phosphorylation state of eNOS is key to blood vessel function."
   Similar news · Read more »
   
6. An eye for an eye: using stem cells to treat damaged eyes and a rare skin disorder
   10-22-2007 · EurekAlert!
   Doctors and scientists in Italy have shown how stem cells can be used to treat damaged eyes and, in combination with gene therapy, a rare and debilitating skin disease.
   Similar news · Read more »
   
7. New mutation that causes atypical hemolytic uremic syndrome identified
   10-30-2006 · EurekAlert!
   Researchers from the University of Newcastle, UK, have identified a novel genetic change that causes one form of atypical hemolytic uremic syndrome (aHUS) a rare, chronic disease that causes kidney failure and which can run in families.
   Similar news · Read more »
   
8. NIH researchers discover protein that appears to regulate bone mass loss, the cause of osteoporosis
   03-05-2007 · EurekAlert!
   An estimated ten million Americans suffer from osteoporosis, and another 34 million Americans are at risk of developing the disease. The basic mechanism behind osteoporosis involves an imbalance between bone mineral formation and loss, but the detailed biological processes that lead to this imbalance are not completely understood. Now researchers at NIAID and colleagues are reporting new insights into the biology of bone loss based on a study of 14 people with a rare genetic disorder called X-linked Hyper IgM Syndrome.
   Similar news · Read more »
   
9. Fosrenol does not further impact cognitive function deterioration in CKD Stage 5 patients
   10-18-2006 · EurekAlert!
   Newly published data from a large, two-year trial in the November Kidney International report on the effects of chronic kidney disease on cognitive function in CKD Stage 5 patients with hyperphosphatemia (high serum phosphorus levels in the blood), treated with phosphate binder therapy. This study is particularly relevant, as there is evidence that individuals with reduced renal function experience a significantly greater decline in cognitive function compared to those with normal renal function.
   Similar news · Read more »
   
10. Promising drug combination may help those with ocular melanoma that has spread
    09-04-2007 · EurekAlert!
    A combination of two drugs shows promise in treating a rare and therapy-resistant type of melanoma that originates in the eye and spreads to other organs, according to a new study led by Duke University Comprehensive Cancer Center researchers.
    Similar news · Read more »